Wolverine Legal Status, FDA 503A Category, and Compounding Access
Where BPC-157 TB-500 stands in FDA's compounding framework today — and what FDA has yet to publish from its July 2026 advisory review. Present-tense facts, cited to FDA; general information, not legal or medical advice.
Access went before an FDA advisory panel — no outcome published yet
The Wolverine legal status story is, right now, a story in motion. Both peptides in the BPC-157 TB-500 blend appeared on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23-24, 2026, listed as bulk drug substances being considered for inclusion on the 503A Bulks List [14]. That was the forward-leaning fact: compounding access to these peptides went before the committee, after FDA staff had proposed against adding either one to the list.
What that review produced is not public: FDA had published no record of the committee's votes as of September 2026. A PCAC meeting is an advisory discussion, not a final FDA decision — no listing, reclassification, or outcome can be assumed, stated, or dated [14]. The honest framing is momentum without a verdict: the question is live, the committee has met, and what FDA's own page shows is what stands until the agency acts.
That current status is unambiguous and present-tense. Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved therapeutic indication. Both were placed in 503A Category 2 in 2023, and FDA's page, current as of April 22, 2026, now lists them as withdrawn nominations; that listing is where this page begins.
What a 503A Category 2 listing means
Under the Federal Food, Drug, and Cosmetic Act, drug compounding is governed by two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [15]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [15].
FDA's interim policy sorted nominated substances into categories. Category 2 substances are those FDA identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [15]. In plain terms: a Category 2 placement warns compounding pharmacies that FDA may act against them for using the ingredient while it holds that listing.
FDA placed both components of the Wolverine blend in Category 2 in September 2023, but its current page records that their nominations were withdrawn and no longer lists either ingredient in that category [16]. FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [16]. FDA likewise identified "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" as a Category 2 bulk substance effective with the same September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information [16]. FDA's own list entry establishes the relationship between TB-500 and Thymosin Beta-4 [16].
Both components went to one July review — no carve-out
<a id="wada"></a>There is no component carve-out in this blend's regulatory status. FDA's current page shows BPC-157 and TB-500 — the latter identified as thymosin beta-4 fragment LKKTETQ — no longer in Category 2 after their nominations were withdrawn; FDA staff nevertheless proposed against listing either substance before the July 23-24, 2026 PCAC meeting [14], [16]. The access picture for one was weighed alongside the other, in the same July discussion.
That shared posture is the cleanest way to read the WADA and FDA status of the pair: two unapproved peptides, both placed in Category 2 on the same 2023 date, both now shown by FDA as withdrawn nominations, both taken up at one advisory meeting. The advisory process does not itself change the 503A Bulks List [15], [14]; FDA staff proposed against listing both ingredients, and FDA had published no record of the committee's votes as of September 2026.
Nothing on this page should be read as asserting that any reclassification has occurred or will occur. Each component is described here as FDA.gov now lists it, a withdrawn nomination that once sat in Category 2; the July 2026 meeting is referenced only as a past discussion whose votes FDA has not published.
How legally compounded peptide access works
In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [15]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [15].
Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is one route to a licensed-prescriber consultation — not a separate legal status. Telehealth does not expand which substances may be compounded, and it does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription [15].
The ingredient-eligibility caveat is the operative limit. FDA's published criteria still control the use of bulk ingredients under sections 503A and 503B, but the agency has not published instructions telling compounders how to treat a nomination that was withdrawn after Category 2 review [15]. The nominations for BPC-157 and TB-500 were withdrawn, and FDA has not answered how a pharmacy should read that change under the ingredient rules. This page describes the general regulatory landscape; it is not medical or legal advice, and it is not an offer to sell or supply any substance.
Access and regulatory questions
Is Wolverine Legal?
Neither component of the Wolverine blend is an FDA-approved drug, and the blend has no approved indication. FDA placed both BPC-157 and TB-500 in 503A Category 2 in September 2023 over significant-safety-risk concerns; its current table now records that the nominations were withdrawn, which does not mean either ingredient is available to a compounder [16], [15]. This is general regulatory information, not legal advice or purchasing guidance.
Can You Get BPC-157 From a Compounding Pharmacy?
FDA placed BPC-157 in 503A Category 2 in September 2023 after identifying significant safety concerns, but its current page records that the nomination was withdrawn and has not said whether a pharmacy may compound it [16]. The 503A/503B bulk-substance rules still govern a compounder's choice of ingredient, but FDA has not spelled out how those rules apply after the BPC-157 nomination was withdrawn [15]. BPC-157 was also on the July 23-24, 2026 PCAC agenda as a candidate, and FDA has not yet published the committee's votes [14].
What Is the FDA 503A Status of Wolverine?
Neither component is FDA-approved. FDA placed both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 in September 2023 and retains the potential-immunogenicity concerns beside their entries, while recording that the two nominations were withdrawn [16]. Both were on the published agenda of the July 23-24, 2026 PCAC meeting as substances being considered for the 503A Bulks List; FDA staff had proposed against listing them, and no decision has been published [14]. The blend itself has no approved therapeutic indication.
Are BPC-157 and TB-500 FDA Approved or Banned by WADA?
Neither is FDA-approved for human use; both entered 503A Category 2 with the September 29, 2023 FDA update, and FDA's page now lists both nominations as withdrawn [16]. Both constituents are also prohibited by the World Anti-Doping Agency — BPC-157 under the non-approved-substances category and TB-500 / Thymosin Beta-4 under the relevant prohibited peptide and tissue-repair categories — in and out of competition.